Psychiatry Research
Volume 121, Issue 3 , Pages 239-252 , 1 January 2004

Neurobiological correlates of diagnosis and underlying traits in patients with borderline personality disorder compared with normal controls

  • Joel Paris

      Affiliations

    • Institute of Community and Family Psychiatry, SMBD-Jewish General Hospital, 4333 Chemin de la Côte Ste. Catherine, Montréal, Québec, Canada, H3T 1E4
    • Department of Psychiatry, McGill University, Montréal, Québec, Canada, H3A 1A1
    • Corresponding Author InformationCorresponding author. Tel.: +1-514-340-8210; fax: +1-514-340-7507
    • ,
  • Hallie Zweig-Frank

      Affiliations

    • Department of Psychology, Concordia University, Montréal, Québec, Canada, H4B 1R6
    • ,
  • N.M.K Ng Ying Kin

      Affiliations

    • Department of Psychiatry, McGill University, Montréal, Québec, Canada, H3A 1A1
    • Douglas Hospital Research Centre, Verdun, Quebec, Canada
    • ,
  • George Schwartz

      Affiliations

    • Department of Psychiatry, McGill University, Montréal, Québec, Canada, H3A 1A1
    • Douglas Hospital Research Centre, Verdun, Quebec, Canada
    • ,
  • Howard Steiger

      Affiliations

    • Department of Psychiatry, McGill University, Montréal, Québec, Canada, H3A 1A1
    • Douglas Hospital Research Centre, Verdun, Quebec, Canada
    • ,
  • N.P.V Nair

      Affiliations

    • Department of Psychiatry, McGill University, Montréal, Québec, Canada, H3A 1A1
    • Douglas Hospital Research Centre, Verdun, Quebec, Canada

Received 5 November 2002 ,Revised 28 August 2003 ,Accepted 1 September 2003.

References 

  1. Barratt E. Impulsive subtraits arousal and information processing. In:  Spence JT,  Izard CE editor. Motivation, Emotion and Personality. New York: Elsevier; 1985;p. 137–146
  2. Buss AH, Durkee A. An inventory for assessing different kinds of hostility. Journal of Consulting Psychology. 1957;21:343–349
  3. Coccaro EF, Siever LJ, Klar H, Maurer G. Serotonergic studies in patients with affective and personality disorders. Archives of General Psychiatry. 1989;46:587–599
  4. Coccaro EF, Lawrence T, Trestman R, Gabriel S. Growth hormone responses to intravenous clonidine challenge correlate with behavioral irritability in psychiatric patients and healthy volunteers. Psychiatry Research. 1991;39:129–139
  5. Coccaro EF, Silverman JM, Klar H, Horvath TB, Siever LJ. Familial correlates of reduced central serotonergic system function in patients with personality disorders. Archives of General Psychiatry. 1994;51:318–324
  6. Coccaro EF, Kavoussi RJ, Sheline YI, Lish JD, Csernansky JG. Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Archives of General Psychiatry. 1996;53:531–536
  7. Coccaro EF. Neurotransmitter function in personality disorders. In:  Silk KR editors. Biology of Personality Disorders. Washington, DC: American Psychiatric Press; 1998;p. 1–26
  8. Coplan JD, Papp LA, Martinez J, Pine D, Rosenblum LA, Cooper T, et al. Persistence of blunted human growth hormone response to clonidine in fluoxetine treated patients with panic disorder. American Journal of Psychiatry. 1995;152:619–622
  9. DeVegvar M-L, Siever LJ, Trestman RL. Impulsivity and serotonin in borderline personality disorder. In:  Silk KR editors. Biological and Neurobehavioral Studies of Borderline Personality Disorder. Washington, DC: American Psychiatric Press; 1998;p. 23–40
  10. Gardner DL, Lucas PB, Cowdry RW. CSF metabolites in borderline personality disorder compared with normal controls. Biological Psychiatry. 1990;28:247–254
  11. Gardner DL, Leibenluft E, O'Leary KM, Cowdry RW. Self-ratings of hostility and anger in borderline personality disorder. Journal of Nervous and Mental Disease. 1991;179:157–161
  12. Garratini S, Mennini T, Samanin R. From fenfluramine racemate to d-fenfluramine. Annals of the New York Academy of Sciences. 1987;499:156–166
  13. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology, Revised 1976. US Department of Health, Education and Welfare, Publication No. ADM 76-338, 179–192. Superintendent of Documents, US Government Printing Office, Washington, DC
  14. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology. 1959;32:50–55
  15. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 1960;23:56–62
  16. Hollander E, Stein DJ, DeCaria CM, Cohen L. Serotonergic sensitivity in borderline personality disorder. American Journal of Psychiatry. 1994;151:277–280
  17. Hollingshead A, Redlich F. Social Class and Mental Illness. New York: Wiley; 1958;
  18. Kennedy SH, Gnam W, Ralevski E, Brown GM. Melatonin responses to clonidine and yohimbine challenges. Journal of Psychiatry and Neuroscience. 1995;20:297–304
  19. Levitan RD, Kaplan AS, Joffe RT, Levitt A, Brown GM. Hormonal and subjective responses to intravenous meta-chlorophenylpiperazine in bulimia nervosa. Archives of General Psychiatry. 1997;54:521–527
  20. Leyton M, Okazawa H, Diksic M, Paris J, Rosa P, Mzengeza S. Brain regional alpha-[11C]methyl-l-tryptophan trapping in impulsive subjects with borderline personality disorder. American Journal of Psychiatry. 2001;158:775–782
  21. Livesley WJ, Jang K, Schroeder ML, Jackson DN. Genetic and environmental factors in personality dimensions. American Journal of Psychiatry. 1993;150:1826–1831
  22. Livesley WJ, Schroeder ML. Dimensions of personality disorder. The DSM-III-R Cluster B diagnoses. Journal of Nervous and Mental Disease. 1991;179:320–328
  23. Loche S, Cappa M, Ghigo E, Faedda A, Lampis A, Carta D, et al. Growth hormone response to oral clonidine test in normal and short children. Journal of Endocrinological Investigation. 1993;16:899–902
  24. Mann JJ, McBride PA, Anderson GM, Mieczkoswiski TA. Platelet and whole blood serotonin content in depressed inpatients. Correlations with actual and life-time psychopathology. Biological Psychiatry. 1992;32:243–257
  25. Mann JJ. The neurobiology of suicide. Nature Medicine. 1998;4:25–30
  26. Martial J, Paris J, Leyton M, Zweig-Frank H, Schwartz G, Teboul E. Neuroendocrine study of serotonergic sensitivity in female borderline personality disorder patients. Biological Psychiatry. 1997;42:737–739
  27. Meltzer HY, Maes M. Pindolol pretreatment blocks stimulation by meta-chorophenylpiperazine of prolactin but not cortisol secretion in normal men. Psychiatry Research. 1995;58:89–98
  28. Moss HB, Yao JK, Panzak G. Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biological Psychiatry. 1990;28:325–338
  29. New, A.S., Trestman, R.L., Mitropoulou, V., Benishay, D.S., Coccaro, E., Silverman, J., Siever, L.J., 1997. Serotonergic function and self-injurious behavior in personality-disorder patients. Psychiatry Research 69, 621–629
  30. O'Keane V, Abel K, Murray RM. Growth hormone response to pyridostigmine in schizophrenia, evidence for cholinergic dysfunction. Biological Psychiatry. 1994;36:582–588
  31. Paris J, Zweig-Frank H, Bond M, Guzder J. Defense styles, hostility and psychological risk factors in male patients with personality disorders. Journal of Nervous and Mental Disease. 1996;184:155–160
  32. Paris J, Zweig-Frank H, Guzder J. Psychological risk factors for borderline personality disorder in female patients. Comprehensive Psychiatry. 1994;35:301–305
  33. Pichot W, Hansenne M, Moreno AG, Ansseau M. Growth hormone response to clonidine in non-depressed patients with a history of suicide attempts. Biological Psychiatry. 1995;38:201–203
  34. Rinne T, Westenberg HG, den Boer JA, van den Brink W. Serotonergic blunting to meta-chlorophenylpiperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients. Biological Psychiatry. 2000;47:548–556
  35. Siever LJ, Davis K. A psychobiological perspective on the personality disorders. American Journal of Psychiatry. 1991;148:1647–1658
  36. Siever LJ, Trestman RL, Coccaro EF, Bernstein D. The growth hormone response to clonidine in acute and remitted depressed male patients. Neuropsychopharmacology. 1992;6:165–177
  37. Siever LJ, New AS, Kirrane R, Novotny S, Koenigsberg H, Grossman R. New biological research strategies for personality disorders. In:  Silk KR editors. Biology of Personality Disorders. Washington, DC: American Psychiatric Press; 1998;p. 27–62
  38. Siever LJ, Buchsbaum MS, New AS, Spiegel-Cohen J. d,l-Fenfluramine response in impulsive personality disorder assessed with 18F-fluorodeoxyglcuose positron emission tomography. Neuropychopharmacology. 1999;20:413–423
  39. Soloff PH, Malone KM, Mann JJ. Serotonin and impulsive-aggression in major depression and Cluster B personality disorders. Neuropsychopharmacology. 1994;10:827S
  40. Soloff PH, Meltzer CC, Greer PJ, Constantine D, Kelly TM. A fenfluramine-activated FDG-PET study of borderline personality disorder. Biological Psychiatry. 2000;47:540–547
  41. Soloff, P.H., Kelly, T.M., Strotmeyer, S.J., Malone, K.M., 2002. Impulsivity, gender, and 5HT in BPD. Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, May
  42. Southwick SM, Yehuda R, Giller EL, Perry BD. Altered platelet alpha-2 adrenergic receptor binding sites in borderline personality disorder. American Journal of Psychiatry. 1990;147:1014–1018
  43. Stahl SM. The human platelet. Archives of General Psychiatry. 1977;34:509–516
  44. Stahl SM, Ciaranello RD, Berger PA. Platelet serotonin in schizophrenia and depression. Advances in Biochemistry and Psychopharmacology. 1982;34:183–198
  45. Steiger H, Ng Ying Kin NMK, Koerner N, Israel M, Lehoux P, Young SN. Implications of impulsive and affective symptoms for serotonin function in bulimia nervosa. Psychological Medicine. 2001;31:85–95
  46. Steiger H, Koerner NM, Engleberg M, Israël M, Ng Ying Kin NMK, Young SN. Self-destructiveness and serotonin function in bulimia nervosa. Psychiatry Research. 2001;103:15–26
  47. Stein DJ, Hollander E, DeCaria CM, Simeon D, Cohen L, Aronowitz B. m-Chlorphenylpiperazine challenge in borderline personality disorder: relationship to neuroendocrine response, clinical response and clinical measures. Biological Psychiatry. 1996;40:508–513
  48. Steinberg BJ, Trestman RL, Siever LJ. The cholinergic and noradrenergic neurotransmitter systems and affective instability in borderline personality disorder. In:  Silk KR editors. Biological and Neurobehavioral Studies of Borderline Personality Disorder. Washington, DC: American Psychiatric Press; 1995;p. 41–62
  49. Verkes RJ, Fekkes D, Zwinderman AH, Hengelveld MW. Platelet serotonin and 3H-paroxetine binding correlated with recurrence of suicidal behavior. Psychopharmacology. 1997;132:89–94
  50. Verkes RJ, Van der Mast RC, Kerkhof AJ, Fekkes D. Platelet serotonin, monoamine oxidase activity and 3H-paroxetine binding related to impulsive suicide attempts and borderline personality disorder. Biological Psychiatry. 1998;43:740–746
  51. Zanarini MC, Gunderson JG, Frankenburg FR. The revised Diagnostic Interview for Borderlines discriminating BPD from other Axis II disorders. Journal of Personality Disorders. 1989;3:10–18
  52. Zanarini MC, Skodol AE, Bender D, Dolan R, Sanislow C, Schaefer E, et al. The collaborative longitudinal personality disorders study: reliability of axis I and II diagnoses. Journal of Personality Disorders. 2000;14:291–299

PII: S0165-1781(03)00237-3

doi: 10.1016/S0165-1781(03)00237-3

Psychiatry Research
Volume 121, Issue 3 , Pages 239-252 , 1 January 2004

Article Tools

* Image Usage & Resolution